Literature DB >> 9062414

Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.

M P Findlay1, D Cunningham, G Morgan, S Clinton, A Hardcastle, G W Aherne.   

Abstract

The increasing interest in 5-fluorouracil (5-FU) modulation and the development of new antifolates has focused attention in recent studies on the expression of the target enzyme thymidylate synthase (TS) as a determinant of drug sensitivity and resistance. Resistance to TS-directed drugs has been shown to occur in vitro and in vivo with increased expression of the enzyme (determined by enzymatic assays as well as protein and gene expression assays). Several studies have evaluated the role of TS as a prognostic indicator of clinical response to chemotherapy containing TS-directed drugs. We have used a polyclonal antibody to recombinant human TS to establish a silver-enhanced immunogold staining method to localize TS in human tumours. Human tumour cell lines with acquired resistance to TS inhibitors owing to increased levels of TS were used to confirm the specificity of immunostaining. Stained sections were evaluated by image analysis. Immunostaining in tumour sections was greatly reduced (>80%) by preabsorption of the antiserum with recombinant TS. The method was used to determine the extent of TS immunostaining in 134 primary human colorectal tumours. The results were then compared with the clinical outcome and response to chemotherapy for the treatment of subsequent metastatic disease. A wide range (approximately 100-fold) of TS immunostaining was observed in these primary tumour sections. Normal mucosal tissue levels were 5-10 times lower than those observed in the adjacent tumour tissue. The values for TS immunostaining did not correlate with clinical endpoints, such as time from diagnosis to relapse, response to chemotherapy for disseminated disease, nor with Dukes' staging. This lack of correlation may be because this group of patients was selected on the basis of their need for palliative chemotherapy and did not include patients who were cured of their disease. Also, primary tumour TS expression may not give a good indication of the TS expression in metastatic lesions. The prognostic significance of TS protein expression in primary and metastatic lesions requires further evaluation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062414      PMCID: PMC2063401          DOI: 10.1038/bjc.1997.159

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.

Authors:  P G Johnston; J C Drake; J Trepel; C J Allegra
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

2.  Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction.

Authors:  T Horikoshi; K D Danenberg; T H Stadlbauer; M Volkenandt; L C Shea; K Aigner; B Gustavsson; L Leichman; R Frösing; M Ray
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

3.  Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue.

Authors:  P G Johnston; C M Liang; S Henry; B A Chabner; C J Allegra
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

4.  Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line.

Authors:  E Chu; S Zinn; D Boarman; C J Allegra
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

5.  Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.

Authors:  S M Swain; M E Lippman; E F Egan; J C Drake; S M Steinberg; C J Allegra
Journal:  J Clin Oncol       Date:  1989-07       Impact factor: 44.544

6.  Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors.

Authors:  C L Van der Wilt; H M Pinedo; K Smid; G J Peters
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

7.  Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy.

Authors:  J L Clark; S H Berger; A Mittelman; F G Berger
Journal:  Cancer Treat Rep       Date:  1987-03

8.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.

Authors:  A L Jackman; G A Taylor; W Gibson; R Kimbell; M Brown; A H Calvert; I R Judson; L R Hughes
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

9.  Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2'-deoxy-uridine-5'-monophosphate.

Authors:  G J Peters; C J van Groeningen; E J Laurensse; H M Pinedo
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

10.  Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694.

Authors:  S J Freemantle; A L Jackman; L R Kelland; A H Calvert; J Lunec
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

View more
  18 in total

1.  Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.

Authors:  Silke Lassmann; Michael Hennig; Robert Rosenberg; Jörg Nährig; Joachim Schreglmann; Friedemann Krause; Manuela Poignee-Heger; Hjalmar Nekarda; Heinz Höfler; Martin Werner
Journal:  Int J Colorectal Dis       Date:  2005-08-13       Impact factor: 2.571

2.  Gene expression and effects of orally active derivatives of fluoropyrimidine on gastric and colorectal cancer.

Authors:  Satoshi Arakawa; Soji Ozawa; Jin Kawase; Hisanori Oshima; Hidetoshi Nagata; Koji Atsuta; Shunji Umemoto
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

3.  A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.

Authors:  Yan Zhang; Junli Ma; Sai Zhang; Ganlu Deng; Xiaoling Wu; Jingxuan He; Haiping Pei; Hong Shen; Shan Zeng
Journal:  Int J Colorectal Dis       Date:  2015-06-09       Impact factor: 2.571

4.  Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.

Authors:  Tian-Li Wang; Luis A Diaz; Katharine Romans; Alberto Bardelli; Saurabh Saha; Gennaro Galizia; Michael Choti; Ross Donehower; Giovanni Parmigiani; Ie-Ming Shih; Christine Iacobuzio-Donahue; Kenneth W Kinzler; Bert Vogelstein; Christoph Lengauer; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

5.  Analysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-Fluorouracil drug response.

Authors:  A Calascibetta; Flavia Contino; S Feo; G Gulotta; M Cajozzo; A Antona; G Sanguedolce; R Sanguedolce
Journal:  J Nucleic Acids       Date:  2010-01-26

6.  Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.

Authors:  Masanori Terashima; Hisataka Fujiwara; Akinori Takagane; Kaoru Abe; Takashi Irinoda; Tsutomu Nakaya; Hitoshi Yonezawa; Kenichi Oyama; Kazuyoshi Saito; Norio Kanzaki; Satoshi Ohtani; Tsuyoshi Nemoto; Yutaka Hoshino; Michihiko Kogure; Mitsukazu Gotoh
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

7.  Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.

Authors:  Chariya Hahnvajanawong; Jariya Chaiyagool; Wunchana Seubwai; Vajarabhongsa Bhudhisawasdi; Nisana Namwat; Narong Khuntikeo; Banchob Sripa; Ake Pugkhem; Wichittra Tassaneeyakul
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

8.  Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?

Authors:  Miriam López-Gómez; Paloma Cejas; María Merino; David Fernández-Luengas; Enrique Casado; Jaime Feliu
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

Review 9.  Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.

Authors:  B Klump; O Nehls; T Okech; C-J Hsieh; V Gaco; F S Gittinger; M Sarbia; F Borchard; A Greschniok; H H Gruenagel; R Porschen; M Gregor
Journal:  Int J Colorectal Dis       Date:  2003-06-21       Impact factor: 2.571

Review 10.  Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review.

Authors:  Andrea Formentini; Doris Henne-Bruns; Marko Kornmann
Journal:  Langenbecks Arch Surg       Date:  2004-08-12       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.